Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Overweight on 89bio, Lowers Price Target to $19

Author: Benzinga Newsdesk | May 18, 2022 06:42am
Piper Sandler analyst Yasmeen Rahimi maintains 89bio (NASDAQ:ETNB) with a Overweight and lowers the price target from $54 to $19.

Posted In: ETNB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist